Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.
SLV 306
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Since the discovery of endothelin (ET)-1 in 1988, the main components of the signalling pathway have become established… Expand
Is this relevant?
2012
2012
AIMS
Inhibition of neutral endopeptidases (NEP) results in a beneficial increase in plasma concentrations of natriuretic peptides… Expand
Is this relevant?
2004
2004
Diabetic nephropathy is a serious complication of diabetes associated with a poor prognosis which deteriorates to end-stage renal… Expand
Is this relevant?
2004
2004
SLV306, a potent neutral endopeptidase (NEP) inhibitor with additional endothelin-converting enzyme (ECE)-inhibitory activity, in… Expand
Is this relevant?
Review
2003
Review
2003
SLV-306 is an orally active mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development by Solvay SA for… Expand
Is this relevant?